by | Jun 20, 2024 | Publications
Nat Commun. 2024 Jun 19;15(1):5255. doi: 10.1038/s41467-024-49625-y. ABSTRACT GPRC5D is an atypical Class C orphan G protein-coupled receptor. Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for therapeutic...
by | Jun 20, 2024 | Publications
BMC Med Genomics. 2024 Jun 19;17(1):164. doi: 10.1186/s12920-024-01937-0. ABSTRACT BACKGROUND: Immunoregulatory drugs regulate the ubiquitin-proteasome system, which is the main treatment for multiple myeloma (MM) at present. In this study, bioinformatics analysis was...
by | Jun 19, 2024 | Publications
Front Oncol. 2024 Jun 4;14:1402106. doi: 10.3389/fonc.2024.1402106. eCollection 2024. ABSTRACT The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic...
by | Jun 19, 2024 | Publications
EJHaem. 2024 May 17;5(3):494-504. doi: 10.1002/jha2.925. eCollection 2024 Jun. ABSTRACT Understanding the impact of induction and maintenance therapy on patients’ quality of life (QoL) is important for treatment selection. This study aims to compare...
by | Jun 19, 2024 | Publications
EJHaem. 2024 Apr 29;5(3):474-484. doi: 10.1002/jha2.894. eCollection 2024 Jun. ABSTRACT Multiple myeloma remains an incurable cancer mostly affecting older adults and is characterized by a series of remission inductions and relapses. This study aims to evaluate the...
by | Jun 19, 2024 | Publications
EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. ABSTRACT Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple...
